^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TK-8001
i
Other names: TK-8001, Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR, MAGE-A1-directed TCR-transduced autologous CD8+ T-cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
T-knife Therap
Drug class:
HLA-A2 inhibitor, MAGE-A1 inhibitor
Related drugs:
9ms
IMAG1NE: A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors (clinicaltrials.gov)
P1/2, N=23, Terminated, T-knife GmbH | N=48 --> 23 | Trial completion date: Jun 2037 --> Jan 2024 | Suspended --> Terminated | Trial primary completion date: Jun 2024 --> Jan 2024; Sponsor decision.
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
|
HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02
|
TK-8001
11ms
IMAG1NE: A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors (clinicaltrials.gov)
P1/2, N=48, Suspended, T-knife GmbH | Recruiting --> Suspended
Trial suspension • Metastases
|
HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02
|
TK-8001
over2years
IMAG1NE: A Phase 1/2, First-in-Human, Open-Label, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/Metastatic MAGE-A1+ Solid Tumors (clinicaltrials.gov)
P1/2, N=48, Recruiting, T-knife GmbH
New P1/2 trial
|
HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02
|
TK-8001
Share via
